Adaptam Therapeutics

High-Level Overview

Adaptam Therapeutics is a biotechnology company developing first-in-class antibody-based therapies for solid tumors, specifically targeting the immunosuppressive myeloid tumor microenvironment, including tumor-associated macrophages (TAMs), through novel glyco-immune checkpoints like glycan-binding proteins and Siglecs[1][3][5]. It serves oncology patients with hard-to-treat cancers where traditional immunotherapies fail, aiming to disrupt the tumor microenvironment (TME) to enable more effective immune responses via antibody-drug conjugates (ADCs) and bispecific antibodies[1][3][5]. Founded as a spin-off from CIC bioGUNE, the company raised €3 million in a pre-seed round in 2025 led by Criteria Bio Ventures, advancing its pipeline into preclinical stages across multiple indications, supported by ERC Proof of Concept grants and other funding[1][3][4][5].

Origin Story

Adaptam Therapeutics was founded in 2023 by Asis Palazon, PhD, who serves as CEO and CSO, spinning out from CIC bioGUNE in Bilbao, Spain, where he was an Ikerbasque Research Professor and Principal Investigator leading the Cancer Immunology and Immunotherapy lab[1][3][4][5]. Palazon's research focused on T cell and myeloid cell biology in immunotherapy efficacy, including breakthroughs in glycobiology published in Nature Communications, which formed the basis for Adaptam's therapies; early support came from a 2021 Caixa Research Health grant and Criteria Bio Ventures[1][5]. Pivotal moments include receiving an ERC Proof of Concept grant and the €3 million pre-seed round in 2025, enabling preclinical advancement, with board additions from investors like Pablo Cironi and Salvatore Cappadona[1][3][5].

Core Differentiators

• Targeted Approach to TME: Unlike broad immunotherapies, Adaptam specifically neutralizes immunosuppressive myeloid cells (e.g., TAMs) via unexplored glyco-immune checkpoints, addressing a key resistance mechanism in solid tumors[1][3][5].
• Pipeline Innovation: Develops ADCs and bispecific antibodies against novel targets like glycan-binding proteins and Siglecs, backed by CIC bioGUNE's glycobiology expertise for first-in-class potential[1][3][5].
• Strong Scientific Foundation: Stemming from peer-reviewed research (e.g., Nature Communications) and grants from ERC and national sources, positioning it for rapid preclinical progress[1][5].
• Funding and Network: €3M pre-seed from Criteria Bio Ventures provides resources and board expertise, complementing academic spin-off advantages[3][5].

Role in the Broader Tech Landscape

Adaptam rides the immuno-oncology trend targeting the TME, where myeloid cells suppress immune attacks, a major hurdle in solid tumor treatments amid rising ADC and bispecific antibody adoption[1][3][5]. Timing aligns with 2025's biotech funding resurgence for precision therapies, fueled by successes like enhanced ADCs and failures of non-TME-focused drugs, with market forces favoring novel checkpoints amid € billions in oncology R&D[3][5]. As a European spin-off, it bolsters Spain's biotech ecosystem (e.g., CIC bioGUNE hub), influences academia-industry translation, and contributes to global efforts against immunotherapy resistance[1][4][5].

Quick Take & Future Outlook

Adaptam is poised to advance its lead programs into IND-enabling studies, leveraging €3M to hit preclinical milestones and pursue IND filings within 2-3 years, potentially partnering with big pharma for clinical trials[3][5]. Trends like AI-driven target discovery, combo therapies with checkpoints, and EU grant expansions will shape its path, amplifying influence in myeloid-targeted immuno-oncology. As TME modulation proves pivotal, Adaptam's glyco-immune focus could redefine solid tumor standards, delivering therapies where others falter and solidifying its pioneer status in next-era cancer immunotherapy[1][3][5].